A therapy that combines herbal extracts to control symptoms of functional gastrointestinal diseases was found to be effective for dyspepsia in a randomized, double-blind, placebo-controlled trial, according to research presented at the 2022 Digestive Disease Week.
This therapy has been around for decades in a variety of forms and has already demonstrated efficacy in previous controlled trials, but this new study used a proprietary formulation, STW 5-II, or Iberogast Advance (Bayer), that